Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
NCT ID: NCT03585517
Last Updated: 2023-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
10 participants
INTERVENTIONAL
2018-07-21
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）
NCT03556982
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05309213
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
NCT03173417
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
NCT03796390
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
NCT06420063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IM23 CART
All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
IM23
T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IM23
T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To be aged 3 to 80 years
* Expression of CD123 in Blast ≥90%
* ECOG score ≤2
* Voluntary participation in the clinical trials and sign the informed consent.
Exclusion Criteria
* Respiratory failure
* CD19 negative
* Disseminated intravascular coagulation
* ALT /AST\>3 x normal value; Creatinine\> 1.5 x normal value; Bilirubin \>2.0 x -normal value
* Hematosepsis or Uncontrolled active infection
* Uncontrolled diabetes
* Abalienation;
* Patients in pregnancy or breast-feeding period
* Previously treatment with any gene therapy products
* Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial
3 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Immunochina Medical Science & Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xian Lu
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YMCART201806
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.